Stocks / NASDAQ / ESSA Pharma Inc.

ESSA Pharma Inc.

Our Opinion

ESSA Pharma Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.

Supporting Evidence:

“The IND application is a  complete description of the chemistry, non-clinical pharmacodynamics and pharmacokinetics, animal toxicology, manufacturing, and other relevant information related to EPI-506.”

Company Description

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR). The Company’s product candidate, EPI-506 is a selective, oral small molecule pro-drug that blocks the N-terminal domain of the AR. EPI-506 is a pro-drug of EPI-002, a stereoisomer of the Company’s discovery compound, EPI-001. The Company is conducting a Phase I/II clinical study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and efficacy of EPI-506 in patients with metastatic CRPC. It is focused on developing EPI-506 as its clinical-development product candidate.  [Source: MarketWatch]

Company Website: